RedHill Biopharma announces publication in journal on Opaganib

RedHill Biopharma (RDHL) announced the new publication of positive in vivo data, in the journal Diabetes, Metabolic Syndrome and Obesity, in an article entitled “Opaganib Promotes Weight Loss and Suppresses High-Fat Diet, or HFD,-Induced Obesity and Glucose Intolerance”. The data indicates that opaganib effectively suppresses the loss of metabolic control in mice on a HFD, suggesting that opaganib, alone and in combination with semaglutide, is associated with improved glucose tolerance, decreased deposition of fat, weight loss and the prevention of weight gain rebound after removal of semaglutide. The global obesity-diabetes drugs market is projected to be worth around $100B by 2034 – largely driven by GLP-1 inhibitors like Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Trulicity and Mounjaro / Zepbound.